Vir Biotechnology swings to FY26 Q2 net income of $80.1 million; revenue rises to $238.9 million
VIR•Q2 earnings and revenue rise
Vir Biotechnology posted Q2 net income of $80.1 million, or $0.48 a share, swinging from a year-ago net loss.
Revenue rose to $238.9 million, driven by $238.9 million in license and collaboration revenue tied to an Astellas upfront payment.
R&D expenses increased to $135.3 million from $97.5 million, due to a $48 million milestone payment to Sanofi.
Cash position and pipeline timing
Cash, cash equivalents and investments ended at about $1.01 billion, up about $198.5 million in the quarter.
Phase 3 ECLIPSE 1 topline data is expected in Q4 2026; guidance says cash will fund operations into H2 2028.
